---
document_datetime: 2023-09-21 22:16:29
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sylvant-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: sylvant-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 13.6105921
conversion_datetime: 2025-12-28 05:10:56.044932
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SYLVANT

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IAIN/0041            | A.1-Administrative change-Changein thename and/oraddressof theMAH                                  | 17/07/2023                          |                                            | SmPC, Labelling and PL          |           |
| IB/0040              | B.I.a.4.c -Change to in-process tests or limits applied during the manufacture of the AS -Deletion | 08/06/2023                          | n/a                                        |                                 |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | of anon-significant in-process test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |          |                                |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|--------------------------------|
| IB/0039     | B.II.f.1.b.5-Stability of FP-Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordancewith an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/02/2023 |     | SmPC     |                                |
| I1/0038     | SubmissionofthereportfromstudyACCELERATE (Advancing Castleman Care with anElectronic LongitudinalRegistry,E-Repository,And Treatment/EffectivenessResearch):AnInternational RegistryforPatientswithCastlemanDisease- NCT02817997listed as anobligationin theAnnexII of theProductInformation. This is a study Report to cover the data collected for 100patientsovera5yearperiodintheACCELERATE Registrystudytocollectinformationorpatientswith Castleman'sDiseasewhoarecandidatestoreceive Sylvantorarecurrentlyreceivingtreatmentwith Sylvant. Theobligationhasnowbeenfulfilled,theAnnexII is updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligationsandconditionsofamarketing authorisation,including theRMP-Implementation of change(s)whichrequire tobefurthersubstantiated bynewadditional data tobesubmittedby theMAH where significant assessment isrequired | 12/01/2023 |     | Annex II | Not applicable                 |
| PSUSA/10254 | PeriodicSafetyUpdateEUSingleassessment-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 01/12/2022 | n/a |          | PRACRecommendation-maintenance |

<div style=\"page-break-after: always\"></div>

| /202204             | siltuximab                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                               |
|---------------------|---------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0035           | A.1-Administrative change-Change in the name and/or addressof theMAH                                    | 09/04/2021 | 29/04/2022 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                               |
| IB/0034             | B.I.e.5.z-Implementation of changesforeseen in an approved change management protocol - Other variation | 13/12/2019 | n/a        |                                  |                                                                                                                                                                                                                                                               |
| PSUSA/10254 /201904 | PeriodicSafetyUpdateEUSingleassessment- siltuximab                                                      | 31/10/2019 | n/a        |                                  | PRACRecommendation-maintenance                                                                                                                                                                                                                                |
| T/0033              | Transfer ofMarketingAuthorisation                                                                       | 26/07/2019 | 03/09/2019 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                               |
| R/0029              | Renewal of the marketing authorisation.                                                                 | 31/01/2019 | 02/04/2019 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, theCHMPconsidered thatthebenefit-riskbalanceof SYLVANT in the approved indicationremainsfavourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0031             | B.II.b.3.z-Change in the manufacturing process of thefinished orintermediateproduct-Othervariation      | 11/02/2019 | n/a        |                                  |                                                                                                                                                                                                                                                               |
| PSUSA/10254 /201804 | PeriodicSafetyUpdateEUSingle assessment- siltuximab                                                     | 31/10/2018 | n/a        |                                  | PRACRecommendation-maintenance                                                                                                                                                                                                                                |
| N/0030              | Minorchangeinlabellingorpackageleafletnot connected with theSPC(Art.61.3 Notification)                  | 04/10/2018 | 02/04/2019 | PL                               |                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| PSUSA/10254 /201710   | PeriodicSafetyUpdateEUSingle assessment- siltuximab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/05/2018   | n/a        |                       | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0026/G             | Thiswas an applicationfor a groupof variations. Updateofsections4.4,4.8,5.1and5.2of theSmPC in order to update the product information following finalresultsfromstudiesCNTO328MCD2001and CNTO328MCD2002listedasimposedobligationin the AnnexII(ANX002 and ANX003).ThePackage Leaflet areupdated accordingly.TheRMPversion4.0 has alsobeensubmitted.In addition,thelist of local representatives (Czech Republic, Lithuania and Portugal) in thePL is beingrevised C.I.4 - Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance | 12/04/2018   | 02/04/2019 | SmPC, Annex II and PL | An open-label, multicentre, non-randomised Phase 2 study assessed thesafety andefficacyofextendedtreatment withsiltuximabin60patientswithMCDwhowere previously enrolled in Study 1 (41 patients) or Study 2 (19 patients). Median duration of siltuximab treatment was 5.52years(range:0.8 to10.8years);more than50%of patientsreceivedsiltuximabtreatmentfor≥5years.Aftera medianof6yearsoffollow-up,noneofthe60patientshad diedandmaintenanceofdiseasecontrolwasdemonstrated in58of60patients. |
| PSUSA/10254 /201704   | PeriodicSafetyUpdateEUSingle assessment - siltuximab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/11/2017   | n/a        |                       | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0025               | B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changestoqualitycontrol testingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 15/08/2017   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0023             | C.I.13 - Other variations not specifically covered elsewhereinthisAnnexwhichinvolvethesubmission ofstudiesto thecompetentauthority                                                                                                                                                                                                                                                                                                                  | 06/07/2017   | n/a        |             |                                |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------|
| IB/0022             | B.II.f.1.b.5-Stability ofFP-Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stabilityprotocol                                                                                                                                                                                                                                                                       | 17/05/2017   | 12/04/2018 | SmPC and PL |                                |
| PSUSA/10254 /201610 | PeriodicSafetyUpdateEUSingle assessment- siltuximab                                                                                                                                                                                                                                                                                                                                                                                                 | 05/05/2017   | n/a        |             | PRACRecommendation-maintenance |
| IB/0021             | B.I.d.1.a.4-Stability of AS -Change in the re-test period/storageperiod-Extensionorintroductionof a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                       | 04/04/2017   | n/a        |             |                                |
| IA/0020/G           | This was an application for a group of variations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerof the finished product,including quality control sites (excludingmanufacturerforbatchrelease) | 03/02/2017   | 11/04/2017 | Annex II    |                                |
| IB/0018             | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                               | 13/01/2017   | 11/04/2017 | SmPC and PL |                                |

<div style=\"page-break-after: always\"></div>

| IB/0017             | B.I.d.1.a.4-Stability of AS -Change in the re-test period/storage period - Extension or introduction of a re-testperiod/storageperiodsupportedbyreal time data                                                                                                                                                                                                                  | 01/12/2016   | n/a        |                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------------|
| PSUSA/10254 /201604 | PeriodicSafetyUpdateEU Single assessment - siltuximab                                                                                                                                                                                                                                                                                                                           | 01/12/2016   | n/a        | PRACRecommendation-maintenance |
| IB/0015             | C.I.11.z-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Othervariation                                                                                                                                                                                                                                         | 27/10/2016   | n/a        |                                |
| IB/0016             | B.I.a.z-Change in manufacture of the AS-Other variation                                                                                                                                                                                                                                                                                                                         | 20/10/2016   | n/a        |                                |
| IB/0014/G           | Thiswas an applicationfor a groupof variations. B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition)for theASora starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product-Other changes to a testprocedure (includingreplacementor addition) | 04/08/2016   | n/a        |                                |
| PSUSA/10254 /201510 | PeriodicSafetyUpdateEUSingle assessment- siltuximab                                                                                                                                                                                                                                                                                                                             | 13/05/2016   | n/a        | PRACRecommendation-maintenance |
| IB/0012             | C.I.z-Changes(Safety/Efficacy)of Human and                                                                                                                                                                                                                                                                                                                                      | 03/05/2016   | 11/04/2017 | SmPC, Annex                    |

<div style=\"page-break-after: always\"></div>

|                     | VeterinaryMedicinalProducts-Othervariation                                                                                                                                           |            |            | II, Labelling  and PL   |                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------|--------------------------------|
| IB/0010             | C.1.11.z-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Othervariation                                               | 02/12/2015 | n/a        |                         |                                |
| PSUSA/10254 /201504 | Periodic Safety Update EU Single assessment - siltuximab                                                                                                                             | 06/11/2015 | n/a        |                         | PRACRecommendation-maintenance |
| IB/0008             | B.II.f.1.d - Stability of FP - Change in storage conditions of thefinishedproductor the diluted/reconstitutedproduct                                                                 | 03/06/2015 | 17/07/2015 | SmPC and PL             |                                |
| PSUSA/10254 /201410 | PeriodicSafetyUpdateEUSingleassessment- siltuximab                                                                                                                                   | 07/05/2015 | n/a        |                         | PRACRecommendation-maintenance |
| N/0007              | Minorchangeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification)                                                                                              | 13/03/2015 | 17/07/2015 | Labelling               |                                |
| IG/0531             | B.II.b.1.a-Replacementor additionofa manufacturingsitefortheFp-Secondarypackaging site                                                                                               | 05/03/2015 | n/a        |                         |                                |
| IA/0005             | A.6-Administrative change -Change in ATC Code/ATCVetCode                                                                                                                             | 26/02/2015 | 17/07/2015 | SmPC                    |                                |
| IB/0003/G           | This was an applicationfor a group of variations. B.I.a.4.b -Change to in-process tests orlimits applied during the manufacture of the AS - Addition of anewin-processtest andlimits | 30/12/2014 | n/a        |                         |                                |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure   |            |            |             |         |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------|
| IB/0002 | B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of the AS                                                                                                                                                                                                                                      | 07/10/2014 | n/a        |             |         |
|         | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                           | 10/07/2014 | 17/07/2015 | SmPC and PL | IB/0001 |